Abstract
Patients with a history of sudden arrhythmic cardiac death (SACD) have a known significant recurrence rate ranging from 30% to 42% at one year. Because of this substantial number, secondary prevention of SACD has been advocated for a long time. Nevertheless, ongoing debate seems to be put to rest by recently published results of several well-designed randomized studies. The results of these secondary prevention trials consistently demonstrated that the implantable cardioverter-defibrillator is the first-choice therapy for secondary prevention of sudden arrhythmic cardiac death or hemodynamically compromising ventricular tachycardia. Thus, it is not very astonishing that these results have led to significant changes in the treatment of patients who have survived sudden cardiac death. Another message, which is supported by recent findings of the MUSST study, derives from the results of the secondary prevention trials: serial electrophysiologic drug testing now seems obsolete.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.